search

Active clinical trials for "Waldenstrom Macroglobulinemia"

Results 21-30 of 336

BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I)

Diffuse Large B Cell LymphomaFollicular Lymphoma6 more

This is a Phase I-II, multi-center, open-label, FIH study comprising of 2 study parts (Phase Ia, Phase Ib). The Phase Ia (dose escalation) part of the study is designed to determine the safety, tolerability, and maximum tolerated dose (MTD)/recommended dose for expansion (RP2D) of BR101801 in subjects with relapsed/refractory B cell lymphoma, chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), and peripheral T cell lymphoma (PTCL). The Phase Ib (dose expansion) part of the study is designed to assess tumor response and safety in specific advanced relapsed/refractory Peripheral T-cell lymphoma(PTCL) at a dose of BR101801 identified in Phase Ia. Once the RP2D has been determined in Phase Ia (dose escalation), Phase Ib (dose expansion) will commence.

Recruiting46 enrollment criteria

Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial...

Waldenstrom Macroglobulinemia

Waldenström's macroglobulinaemia (WM) is a rare type of slow growing lymphoma. It develops when white blood cells grow abnormally. Typically a disease of the elderly, the median age of presentation is >70 years and the current treatment for WM is unsatisfactory, with incomplete responses and inevitable recurrence. Therefore there is a need to find alternative treatments that are more effective, leading to lasting responses and improved quality of life. The RAINBOW study is a phase 2-3 trial assessing 'chemotherapy free' treatment as primary therapy for WM which can potentially improve response outcome, durability and importantly, reduce toxicity for WM patients. This approach will be done using the drug Ibrutinib, which in combination with rituximab (RI) will be the experimental arm. As there is no agreed standard on first-line therapy for WM, the control arm is the current treatment based on the most recently published clinical trial results. The control arm consists of rituximab, cyclophosphamide and dexamethasone (DCR), and is widely recommended by international consensus as appropriate treatment for first-line therapy for WM. In this study, 148 adults (aged ≥ 18 years) with treatment naïve WM will be randomised on a 1:1 ratio to either the treatment or control arm. Randomised treatment lasts for a maximum of 6 cycles and response will be assessed following 3 cycles of treatment and completion of randomised treatment at approximately 24 weeks after commencing treatment. RI patients may then have up to 5 years of Ibrutinib monotherapy. Patients will be seen regularly during treatment and then every 3 months for 5 years after treatment discontinuation. Patients will enter annual follow up for survival until the end of trial (including progressed patients). The study will be conducted at NHS hospitals and is expected to last 9 years and 6 months.

Recruiting47 enrollment criteria

A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

Mantle Cell LymphomaPeripheral T-cell Lymphoma (PTCL)8 more

This study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies. Up to 12 evaluable patients with a diagnosis of relapsed or refractory lymphoid malignancies are expected to participate.

Recruiting45 enrollment criteria

Dasatinib In Waldenström Macroglobulinemia

Waldenstrom MacroglobulinemiaDASATINIB

This is Phase I pilot, single center study designed to explore the safety of Dasatinib in symptomatic Waldenström Macroglobulinemia participants who are progressing on ibrutinib therapy with BTK Cys481 or PLCG2 mutations

Recruiting50 enrollment criteria

APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström...

Waldenstrom Macroglobulinemia

Phase Ib/II study of safety, tolerability, efficacy and PK of APG-2575 as a single agent or in combination with other therapeutic agents including ibrutinib or rituximab.

Recruiting64 enrollment criteria

Study of SGR-1505 in Mature B-Cell Neoplasms

Mature B-Cell NeoplasmNon Hodgkin Lymphoma26 more

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-1505.

Recruiting9 enrollment criteria

Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory...

Follicular B-cell Non-Hodgkin's LymphomaMantle Cell Lymphoma Recurrent7 more

Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory B-Cell NHL or CLL

Recruiting45 enrollment criteria

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)6 more

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.

Recruiting27 enrollment criteria

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

B-cell MalignancyMarginal Zone Lymphoma7 more

Study consists of two main parts to explore BGB-16673 recommended dosing, a Part 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a part 2 (dose expansion cohorts)

Recruiting12 enrollment criteria

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or...

Grade 1 Follicular LymphomaGrade 2 Follicular Lymphoma6 more

This phase II trial studies the effect of acalabrutinib and obinutuzumab in treating patients with follicular lymphoma or other indolent non-Hodgkin lymphoma for which the patient has not received treatment in the past (previously untreated). Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with obinutuzumab may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Giving acalabrutinib and obinutuzumab may kill more cancer cells.

Recruiting41 enrollment criteria
1234...34

Need Help? Contact our team!


We'll reach out to this number within 24 hrs